ADARx prices IPO at $17 per share, AbbVie to buy stakeSep 25FinancingAbbVieADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRXSep 4FinancingADARx Pharmaceuticals, Inc.inclisiran sodium
Novartis updates Leqvio label; MS study recruiting, thyroid study not yet recruitingAug 21Weekly roundup, 8 itemsGIA632inclisiran
Silexion advances SIL204 into Phase 2/3 trial, reports Q2 2026 resultsAug 14Quarterly updateSilexion Therapeutics Corp
Silence Therapeutics prices $175 million ADS offering at $13.50 per shareAug 12FinancingSilence Therapeutics plc
Silence Therapeutics reports positive Phase 2 topline data for divesiran in polycythemia veraAug 10Clinical readoutSilence Therapeutics plc
Silence Therapeutics reports Q2 2026 results and divesiran trial progressAug 10Quarterly updateSilence Therapeutics plc
Phio reports Q2 2026 results, sets Q3 FDA meeting on PH-762 pathAug 6Quarterly updatePhio Pharmaceuticals Corp.
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updatesAug 5Quarterly updateSarepta Therapeutics, Inc.
Atrium Therapeutics recruiting for Phase 1/2 ATR 1072 trial in PRKAG2 SyndromeJul 31Trial updateATR-1072Atrium Therapeutics
Sign inSign in